RAPHAEL PHARMACEUTICAL INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.64 USD | +6.49% |
|
-.--% | +64.00% |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 1.85Cr 154.5Cr |
|---|---|---|---|---|---|
| Net income 2022 | -30L -25Cr | Net income 2023 | -10L -8.35Cr | EV / Sales 2022 * | - |
| Net cash position 2022 | 3L 2.4Cr | Net cash position 2023 | 2L 1.92Cr | EV / Sales 2023 | - |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
-13
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 48.01% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +6.49% | ||
| 1 month | +64.00% | ||
| 3 months | +64.00% | ||
| 6 months | +64.00% | ||
| Current year | +64.00% |
1 month
1.00
1.64
Current year
1.001.64
1 year
0.601.67
3 years
0.602.50
5 years
0.602.50
10 years
0.602.50
Raphael Pharmaceutical Inc. is a pharmaceutical drug research and development company. The Company is focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol (CBD) oil. The Company is in pre-clinical development stage for its lead product candidate, rheumatoid arthritis (RA), for the treatment of RA. In addition, the Company is also developing a pharmaceutical drug product for the treatment of hyperinflammatory syndrome inflammation related to COVID-19. The Companyâs discovery platform focuses the use of CBD oil, one of the cannabinoids in cannabis plants, as the active pharmaceutical ingredient (API), for its RA product candidate and COVID-19 product candidate.
| 1st Jan change | Capi. | |
|---|---|---|
| +64.00% | 3.07Cr | |
| +51.85% | 5.79TCr | |
| +41.11% | 4.03TCr | |
| -5.25% | 3.99TCr | |
| -5.16% | 2.85TCr | |
| +12.79% | 2.64TCr | |
| -20.18% | 1.93TCr | |
| +30.88% | 1.24TCr | |
| +0.61% | 1.22TCr | |
| +25.06% | 1.22TCr |
- Stock Market
- Equities
- RAPH Stock
